about
Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometryHair analysis and detectability of single dose administration of androgenic steroid estersDrug Use on Mont Blanc: A Study Using Automated Urine CollectionLongitudinal evaluation of the isotope ratio mass spectrometric data: towards the 'isotopic module' of the athlete biological passport?Non-targeted LC-MS based metabolomics analysis of the urinary steroidal profile.Human hepatoma cell lines on gas foaming templated alginate scaffolds for in vitro drug-drug interaction and metabolism studies.Smoking habits of italian athletes undergoing anti-doping control.Analysis of exemestane and 17β-hydroxyexemestane in human urine by gas chromatography/mass spectrometry: development and validation of a method using MO-TMS derivatives.A rapid screening LC-MS/MS method based on conventional HPLC pumps for the analysis of low molecular weight xenobiotics: application to doping control analysis.Improved ultrasonic-based sample treatment for the screening of anabolic steroids by gas chromatography/mass spectrometry.A gas chromatography/mass spectrometry method for the determination of sildenafil, vardenafil and tadalafil and their metabolites in human urine.Speeding up the process urine sample pre-treatment: some perspectives on the use of microwave assisted extraction in the anti-doping field.Mass spectrometric characterization of tamoxifene metabolites in human urine utilizing different scan parameters on liquid chromatography/tandem mass spectrometry.Effects of propyphenazone and other non-steroidal anti-inflammatory agents on the synthetic and endogenous androgenic anabolic steroids urinary excretion and/or instrumental detection.A simplified procedure for the analysis of formoterol in human urine by liquid chromatography-electrospray tandem mass spectrometry: application to the characterization of the metabolic profile and stability of formoterol in urine.13C/12C isotope ratio MS analysis of testosterone, in chemicals and pharmaceutical preparations.Plasma and urinary markers of oral testosterone undecanoate misuse.Fast screening of anabolic steroids and other banned doping substances in human urine by gas chromatography/tandem mass spectrometry.Drug-drug interaction and doping, part 2: an in vitro study on the effect of non-prohibited drugs on the phase I metabolic profile of stanozolol.Drug-drug interaction and doping, part 1: an in vitro study on the effect of non-prohibited drugs on the phase I metabolic profile of toremifene.A mass spectrometric approach for the study of the metabolism of clomiphene, tamoxifen and toremifene by liquid chromatography time-of-flight spectroscopy.Liposomes as potential masking agents in sport doping. Part 1: analysis of phospholipids and sphingomyelins in drugs and biological fluids by aqueous normal-phase liquid chromatography-tandem mass spectrometry.Characterization of the biotransformation pathways of clomiphene, tamoxifen and toremifene as assessed by LC-MS/(MS) following in vitro and excretion studies.Investigation on the application of DNA forensic human identification techniques to detect homologous blood transfusions in doping control.Fast IRMS screening of pseudoendogenous steroids in doping analyses.Effect of non-prohibited drugs on the phase II metabolic profile of morphine. An in vitro investigation for doping control purposes.Fast GC-MS method for the simultaneous screening of THC-COOH, cocaine, opiates and analogues including buprenorphine and fentanyl, and their metabolites in urine.Development and validation of a GC-C-IRMS method for the confirmation analysis of pseudo-endogenous glucocorticoids in doping control.Doping control container for urine stabilization: a pilot study.Application of DNA-based forensic analysis for the detection of homologous transfusion of whole blood and of red blood cell concentrates in doping control.Liposomes as potential masking agents in sport doping. Part 2: Detection of liposome-entrapped haemoglobin by flow cytofluorimetry.In vitro evaluation of the effects of anti-fungals, benzodiazepines and non-steroidal anti-inflammatory drugs on the glucuronidation of 19-norandrosterone: implications on doping control analysis.Detection of formestane abuse by mass spectrometric techniques.Reference ranges for the urinary steroid profile in a Latin-American population.Urinary excretion profiles of toremifene metabolites by liquid chromatography-mass spectrometry. Towards targeted analysis to relevant metabolites in doping control.Combined chemical and biotechnological production of 20βOH-NorDHCMT, a long-term metabolite of Oral-Turinabol (DHCMT).SFC-MS/MS as an orthogonal technique for improved screening of polar analytes in anti-doping control.A fast gas chromatography/mass spectrometry method for the determination of stimulants and narcotics in urine.Metabolism of boldione in humans by mass spectrometric techniques: detection of pseudoendogenous metabolites.A further insight on the metabolic profile of the nuclear receptor Rev-erb agonist, SR9009
P50
Q28292326-F86FF793-D597-4DEA-BCDA-159385603E2FQ28371181-70E56DA6-AAF1-4B89-B26E-E29EB69FBC8FQ28552629-42B1A0C2-5383-43BA-8BF3-E475FF60FC62Q31136250-F77539F2-32F1-433A-A907-CABD97DBEAB4Q38738356-AD5C7479-C8D5-47FC-A8EA-43066E271642Q40443212-43B5E24F-3840-4CD8-B8C2-5E290BC6B9A4Q41468437-5DD1C9CE-32B1-45A5-97B4-64491C45CFE1Q42848977-8F1C58EF-C77D-4BD6-84B7-6B9618F3224DQ42917126-3E227AE8-3D1D-474F-9C72-078315F57C9EQ42968705-3F7DFDD7-E97C-4ACF-9CFD-2F5CB93EB1D8Q43058806-FE55D0FB-BFC8-49A0-993C-A8746B8DCBF8Q43074494-864DB4C8-F49E-4002-AB12-136D5D943E71Q43148444-7F68348A-CB48-4EED-99F2-9B6C35AA55D0Q43232798-7A6DE4BC-57F5-48DC-ACD6-9898D5E68C43Q43480028-05793AB9-FCCD-49E6-9EC2-D53E335337B4Q43555754-5BEAEB0C-705C-43F2-A2F9-005C732DAC0BQ43812322-F74FC8C5-8CC1-47F2-A295-7CA2B939B135Q44176086-E4AE03FC-E733-4A19-9008-D78BE8C13995Q44562239-92134D1B-A40E-49EC-AF7D-156EB54CC841Q45949148-B094E562-BDB1-447D-A6FC-8378B3FA3077Q46425442-CDB3C694-2328-4351-8B6A-6CA9D3E6CF72Q46598775-837F69B3-D4AC-4592-9BEE-9D7B014785B0Q46915581-D86922EC-8E44-4FF3-BF25-837A373F5FF2Q47763364-7C4D0FC4-8238-461A-B8F2-FFEB53746183Q47793568-041B359B-9C6B-4D04-939E-2E1C5335CF82Q48240063-85A8F91B-F032-493F-A03B-94C2B0661929Q48305385-743853AF-76E8-4D97-B833-C834C6B9B426Q48911331-693F21F4-94D9-4611-B0F5-CB3683141831Q49031132-FBDE1015-1DE5-4526-9040-2A8666152CD8Q50240293-6CE1F219-B4CF-4380-BFF7-ACF9DE088A87Q50876699-C3980243-4212-422B-AF64-EF753D8A2B57Q50922401-6E6A160A-C95E-4009-9D26-10ADA2A8F2CFQ51024470-A12D8C54-49E5-4B21-9346-91BF576C7611Q51279047-01DC61BC-F9A1-4393-8314-A298933100C3Q51496200-2D8C18F3-AF68-443C-BD72-2930BF1F74DBQ52807460-B497FC06-84EF-48C7-9989-AA311F4D5F64Q52848405-CADDA5FF-0B9D-46F9-AE7B-0FE697544C88Q53066998-5AFF4161-E1D3-478D-B5A0-00BE4B60C3F7Q54562614-543D3BA2-BCAD-454F-938A-3241B1A7E5A7Q58610033-B97EB8F9-1F1F-4C02-ABFF-24E6A4E83E69
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Xavier de la Torre
@ast
Xavier de la Torre
@en
Xavier de la Torre
@es
Xavier de la Torre
@nl
Xavier de la Torre
@sl
type
label
Xavier de la Torre
@ast
Xavier de la Torre
@en
Xavier de la Torre
@es
Xavier de la Torre
@nl
Xavier de la Torre
@sl
prefLabel
Xavier de la Torre
@ast
Xavier de la Torre
@en
Xavier de la Torre
@es
Xavier de la Torre
@nl
Xavier de la Torre
@sl
P106
P1153
6603587818
P21
P31
P496
0000-0001-8037-6750